Patents by Inventor Eric N. Olson

Eric N. Olson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240226334
    Abstract: Provided herein are gene therapy methods, vectors and constructs for the treatment of Duchenne Muscular Dystrophy in a subject.
    Type: Application
    Filed: May 24, 2022
    Publication date: July 11, 2024
    Applicant: The Board of Regents of The University of Texas System
    Inventors: Eric N. OLSON, Yu ZHANG, Rhonda BASSEL-DUBY
  • Publication number: 20240165271
    Abstract: Duchenne muscular dystrophy (DMD) is a fatal muscle disease caused by the lack of dystrophin, which maintains muscle membrane integrity. Provided herein are methods of using adenine base editor (ABE) to modify splice sites of the dystrophin gene, causing skipping or refraining of common DMD exon deletion mutations, restoring dystrophin expression. Also provided herein are methods of using prime editing to reframe the dystrophin open reading frame and restore dystrophin expression.
    Type: Application
    Filed: March 25, 2022
    Publication date: May 23, 2024
    Applicant: The Board of Regents of The University of Texas System
    Inventors: Eric N. OLSON, Francesco CHEMELLO, Rhonda BASSEL-DUBY
  • Publication number: 20230241249
    Abstract: Disclosed are methods of treating a subject, such as those having or at risk of cardiomyopathies, with an effective amount of a recombinant adeno-associated virus (rAAV) virion, the rAAV virion comprising an AAV capsid and an expression cassette comprising a polynucleotide encoding a DWORF polypeptide operatively linked to a promoter. Compositions and kits relating to the same are also disclosed.
    Type: Application
    Filed: July 6, 2021
    Publication date: August 3, 2023
    Applicant: The Board of Regents of The University of Texas System
    Inventors: Eric N. OLSON, Rhonda S. BASSEL-DUBY, Benjamin R. NELSON, Catherine A. MAKAREWICH
  • Publication number: 20220072156
    Abstract: Duchenne muscular dystrophy (DMD) is an inherited X-linked disease caused by mutations in the gene encoding dystrophin, a protein required for muscle fiber integrity. The disclosure reports CRISPR/Cas9-mediated gene editing (Myo-editing) is effective at correcting the dystrophin gene mutation in the mdx mice, a model for DMD. Further, the disclosure reports optimization of germline editing of mdx mice by engineering the permanent skipping of mutant exon (exon 23) and extending exon skipping to also correct the disease by post-natal delivery of adeno-associate virus (AAV). AAV-mediated Myo-editing can efficiently rescue the reading frame of dystrophin in mdx mice in vivo. The disclosure reports means of Myo-editing-mediated exon skipping has been successfully advanced from somatic tissues in mice to human DMD patients-derived iPSCs (induced pluripotent stem cells).
    Type: Application
    Filed: August 17, 2021
    Publication date: March 10, 2022
    Applicant: The Board of Regents of the University of Texas System
    Inventors: Eric N. OLSON, Chengzu LONG, John R. McANALLY, John M. SHELTON, Rhonda BASSEL-DUBY
  • Publication number: 20210380650
    Abstract: The present disclosure describes a new native peptide designated herein as Dwarf Open Reading Frame, or DWORF. This peptide enhances the apparent activity of the SERCA pump, is positively inotropic and lusitropic, and therefore is provided as a therapeutic agent for disorders characterized by cytosolic calcium overload.
    Type: Application
    Filed: August 2, 2021
    Publication date: December 9, 2021
    Applicant: The Board of Regents of the University of Texas System
    Inventors: Eric N. OLSON, Rhonda S. BASSEL-DUBY, Catherine A. MAKAREWICH, Benjamin R. NELSON
  • Patent number: 11166949
    Abstract: The present disclosure relates to the identification of Nurr1 as a key regulator of metabolism, and the use of Nurr1 agonist to treat metabolic disorders such as diabetes, obesity, metabolic syndrome and hepatic steatosis.
    Type: Grant
    Filed: April 26, 2017
    Date of Patent: November 9, 2021
    Assignee: The Board of Regents of The University of Texas System
    Inventors: Eric N. Olson, Rhonda Bassel-Duby, Leonela Amoasii
  • Patent number: 11111278
    Abstract: The present disclosure describes a new native peptide designated herein as Dwarf Open Reading Frame, or DWORF. This peptide enhances the apparent activity of the SERCA pump, is positively inotropic and lusitropic, and therefore is provided as a therapeutic agent for disorders characterized by cytosolic calcium overload.
    Type: Grant
    Filed: January 15, 2020
    Date of Patent: September 7, 2021
    Assignee: The Board of Regents of the University of Texas System
    Inventors: Eric N. Olson, Rhonda S. Bassel-Duby, Catherine A. Makarewich, Benjamin R. Nelson
  • Publication number: 20210180023
    Abstract: The present disclosure involves the use of reprogramming factors including AKT1, GATA4, TBX5, MEF2C, HAND2 and either ZNF281 or AS-CL1 to reprogram adult non-cardiomyocytes, such as cardiac fibroblasts into cardiomyocytes, both in vitro and in vivo. Such methods find particular use in the treatment of patients post-myocardial infarction to prevent or limit scarring and to promote myocardial repair.
    Type: Application
    Filed: June 4, 2018
    Publication date: June 17, 2021
    Applicant: The Board of Regents of the University of Texas System
    Inventors: Eric N. OLSON, Huanyu ZHOU, Rhonda BASSEL-DUBY
  • Publication number: 20200370042
    Abstract: The disclosure provides a method for treating or preventing Duchene Muscular Dystrophy (DMD) in a subject in need thereof, the method comprising administering to the subject a Cas9 nuclease or a sequence encoding a Cas9 nuclease, and a gRNA or a sequence encoding a gRNA, wherein the gRNA targets a splice donor or splice acceptor site of the dystrophin gene. The administering restores dystrophin expression in at least a subset of the subjects cardiomyocytes, and may at least partially or fully restore cardiac contractility.
    Type: Application
    Filed: January 31, 2019
    Publication date: November 26, 2020
    Applicant: The Board of Regents of the University of Texas System
    Inventors: Eric N. OLSON, Chengzu LONG
  • Publication number: 20200260698
    Abstract: CRISPR/Cas9-mediated genome editing holds clinical potential for treating genetic diseases, such as Duchenne muscular dystrophy (DMD), which is caused by mutations in the dystrophin gene and absence or deficiency of dystrophin protein in striated muscle. Provided herein are compositions and methods for treating DMD caused by mutations in the dystrophin Actin Binding Domain 1 (ABD-1). The compositions and method described herein can be used to remove mutant sequences in dystrophin ABD-1 to generate a corrected DMD protein that, while lacking one or more exons (e.g., exons 3-9), retains important functional properties.
    Type: Application
    Filed: August 17, 2018
    Publication date: August 20, 2020
    Applicant: The Board of Regents of the University of Texas System
    Inventors: Viktoriia KYRYCHENKO, Eric N. OLSON, Rhonda BASSEL-DUBY
  • Publication number: 20200190511
    Abstract: The present invention relates to the identification of a microRNA family, designated miR-29a-c, that is a key regulator of fibrosis in cardiac tissue. The inventors show that members of the miR-29 family are down-regulated in the heart tissue in response to stress, and are up-regulated in heart tissue of mice that are resistant to both stress and fibrosis. Also provided are methods of modulating expression and activity of the miR-29 family of miRNAs as a treatment for fibrotic disease, including cardiac hypertrophy, skeletal muscle fibrosis other fibrosis related diseases and collagen loss-related disease.
    Type: Application
    Filed: July 11, 2019
    Publication date: June 18, 2020
    Inventors: Eric N. Olson, Eva van Rooij
  • Publication number: 20200140502
    Abstract: The present disclosure describes a new native peptide designated herein as Dwarf Open Reading Frame, or DWORF. This peptide enhances the apparent activity of the SERCA pump, is positively inotropic and lusitropic, and therefore is provided as a therapeutic agent for disorders characterized by cytosolic calcium overload.
    Type: Application
    Filed: January 15, 2020
    Publication date: May 7, 2020
    Applicant: The Board of Regents of the University of Texas System
    Inventors: Eric N. OLSON, Rhonda S. BASSEL-DUBY, Catherine A. MAKAREWICH, Benjamin R. NELSON
  • Patent number: 10570183
    Abstract: The present disclosure describes a new native peptide designated herein as Dwarf Open Reading Frame, or DWORF. This peptide enhances the apparent activity of the SERCA pump, is positively inotropic and lusitropic, and therefore is provided as a therapeutic agent for disorders characterized by cytosolic calcium overload.
    Type: Grant
    Filed: April 19, 2017
    Date of Patent: February 25, 2020
    Assignee: The Board of Regents of the University of Texas System
    Inventors: Eric N. Olson, Rhonda S. Bassel-Duby, Catherine A. Makarewich, Benjamin R. Nelson
  • Publication number: 20190382732
    Abstract: The present disclosure describes the fusogenic promoting activity of the Myomixer protein. This polypeptide, when expressed in non-muscle cells with the Myomaker protein, is able to increase fusion of the cell with a muscle cell, but not with other non-muscle cells, as compared to cells only expression the Myomaker protein. The use of this protein and cells expressing it in the delivery of exogenous genetic material to muscle cells also is described.
    Type: Application
    Filed: February 14, 2018
    Publication date: December 19, 2019
    Applicant: The Board of Regents of the University of Texas System
    Inventors: Eric N. OLSON, Pengpeng BI
  • Patent number: 10392618
    Abstract: The present invention relates to the identification of a microRNA family, designated miR-29a-c, that is a key regulator of fibrosis in cardiac tissue. The inventors show that members of the miR-29 family are down-regulated in the heart tissue in response to stress, and are up-regulated in heart tissue of mice that are resistant to both stress and fibrosis. Also provided are methods of modulating expression and activity of the miR-29 family of miRNAs as a treatment for fibrotic disease, including cardiac hypertrophy, skeletal muscle fibrosis other fibrosis related diseases and collagen loss-related disease.
    Type: Grant
    Filed: June 30, 2017
    Date of Patent: August 27, 2019
    Assignee: THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Eric N. Olson, Eva van Rooij
  • Publication number: 20190134021
    Abstract: The present disclosure relates to the identification of Nurr1 as a key regulator of metabolism, and the use of Nurr1 agonist to treat metabolic disorders such as diabetes, obesity, metabolic syndrome and hepatic steatosis.
    Type: Application
    Filed: April 26, 2017
    Publication date: May 9, 2019
    Applicant: The Board of Regents of the University of Texas System
    Inventors: Eric N. OLSON, Rhonda BASSEL-DUBY, Leonela AMOASII
  • Publication number: 20180163204
    Abstract: The present invention relates to the identification of a microRNA family, designated miR-29a-c, that is a key regulator of fibrosis in cardiac tissue. The inventors show that members of the miR-29 family are down-regulated in the heart tissue in response to stress, and are up-regulated in heart tissue of mice that are resistant to both stress and fibrosis. Also provided are methods of modulating expression and activity of the miR-29 family of miRNAs as a treatment for fibrotic disease, including cardiac hypertrophy, skeletal muscle fibrosis other fibrosis related diseases and collagen loss-related disease.
    Type: Application
    Filed: June 30, 2017
    Publication date: June 14, 2018
    Inventors: Eric N. OLSON, Eva van ROOIJ
  • Patent number: 9937156
    Abstract: The present disclosure concerns uses for isoxazole compounds or salts or analogs thereof for the treatment of wounds. The present disclosure also concerns devices for delivering a isoxazole compound or salts or an analogs thereof to a wound site.
    Type: Grant
    Filed: October 16, 2014
    Date of Patent: April 10, 2018
    Assignee: The Board of Regents of the University of Texas System
    Inventors: Eric M. Small, Eric N. Olson
  • Publication number: 20170298107
    Abstract: The present disclosure describes a new native peptide designated herein as Dwarf Open Reading Frame, or DWORF. This peptide enhances the apparent activity of the SERCA pump, is positively inotropic and lusitropic, and therefore is provided as a therapeutic agent for disorders characterized by cytosolic calcium overload.
    Type: Application
    Filed: April 19, 2017
    Publication date: October 19, 2017
    Inventors: Eric N. Olson, Rhonda S. Bassel-Duby, Catherine A. Makarewich, Benjamin R. Nelson
  • Patent number: 9719088
    Abstract: The present invention relates to the identification of a microRNA family, designated miR-29a-c, that is a key regulator of fibrosis in cardiac tissue. The inventors show that members of the miR-29 family are down-regulated in the heart tissue in response to stress, and are up-regulated in heart tissue of mice that are resistant to both stress and fibrosis. Also provided are methods of modulating expression and activity of the miR-29 family of miRNAs as a treatment for fibrotic disease, including cardiac hypertrophy, skeletal muscle fibrosis other fibrosis related diseases and collagen loss-related disease.
    Type: Grant
    Filed: January 8, 2015
    Date of Patent: August 1, 2017
    Assignee: THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Eric N. Olson, Eva van Rooij